Q-omics provides the consensus-scored DDX50P2 profile across patient tissues and cancer cell-line models. DDX50P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DDX50P2 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, DDX50P2 RNA expression shows 9,082 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where DDX50P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX50P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX50P2 survival associations across molecular data types. DDX50P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX50P2 RNA expression–survival associations across cancer types. High DDX50P2 expression shows unfavorable associations in ACC, LUSC, MESO and BRCA, but favorable associations in SKCM and DLBC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DDX50P2 RNA expression.
This table summarizes DDX50P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DDX50P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX50P2 shows lower tumor expression in THCA and PRAD and higher tumor expression in COAD, HNSC, LIHC and LUAD. The COAD box plot shows higher DDX50P2 RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p = .002).
This table shows molecular features associated with DDX50P2 in patient tissues and cancer cell lines. In patient samples, DDX50P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
